ILLUMINA INC (ILMN) Fundamental Analysis & Valuation

NASDAQ:ILMN • US4523271090

129.56 USD
-3.33 (-2.51%)
At close: Mar 3, 2026
129.04 USD
-0.52 (-0.4%)
Pre-Market: 3/4/2026, 4:36:38 AM

This ILMN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, ILMN scores 6 out of 10 in our fundamental rating. ILMN was compared to 57 industry peers in the Life Sciences Tools & Services industry. ILMN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ILMN has a correct valuation and a medium growth rate. This makes ILMN very considerable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. ILMN Profitability Analysis

1.1 Basic Checks

  • In the past year ILMN was profitable.
  • In the past year ILMN had a positive cash flow from operations.
  • In multiple years ILMN reported negative net income over the last 5 years.
  • In the past 5 years ILMN always reported a positive cash flow from operatings.
ILMN Yearly Net Income VS EBIT VS OCF VS FCFILMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B -2B -3B -4B

1.2 Ratios

  • ILMN has a better Return On Assets (12.79%) than 96.49% of its industry peers.
  • The Return On Equity of ILMN (31.22%) is better than 96.49% of its industry peers.
  • With an excellent Return On Invested Capital value of 13.63%, ILMN belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
Industry RankSector Rank
ROA 12.79%
ROE 31.22%
ROIC 13.63%
ROA(3y)-6.03%
ROA(5y)-9.81%
ROE(3y)-13.51%
ROE(5y)-20.03%
ROIC(3y)N/A
ROIC(5y)N/A
ILMN Yearly ROA, ROE, ROICILMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • The Profit Margin of ILMN (19.57%) is better than 92.98% of its industry peers.
  • ILMN's Profit Margin has been stable in the last couple of years.
  • The Operating Margin of ILMN (20.29%) is better than 87.72% of its industry peers.
  • ILMN's Operating Margin has improved in the last couple of years.
  • ILMN's Gross Margin of 66.61% is amongst the best of the industry. ILMN outperforms 91.23% of its industry peers.
  • ILMN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.29%
PM (TTM) 19.57%
GM 66.61%
OM growth 3Y36.82%
OM growth 5Y2.01%
PM growth 3YN/A
PM growth 5Y-0.68%
GM growth 3Y0.64%
GM growth 5Y-0.57%
ILMN Yearly Profit, Operating, Gross MarginsILMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

7

2. ILMN Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ILMN is creating some value.
  • ILMN has less shares outstanding than it did 1 year ago.
  • ILMN has more shares outstanding than it did 5 years ago.
  • ILMN has a better debt/assets ratio than last year.
ILMN Yearly Shares OutstandingILMN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ILMN Yearly Total Debt VS Total AssetsILMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • ILMN has an Altman-Z score of 4.35. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 4.35, ILMN belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
  • The Debt to FCF ratio of ILMN is 2.14, which is a good value as it means it would take ILMN, 2.14 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.14, ILMN belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
  • ILMN has a Debt/Equity ratio of 0.55. This is a neutral value indicating ILMN is somewhat dependend on debt financing.
  • ILMN has a worse Debt to Equity ratio (0.55) than 64.91% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for ILMN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.14
Altman-Z 4.35
ROIC/WACC1.31
WACC10.42%
ILMN Yearly LT Debt VS Equity VS FCFILMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 2.08 indicates that ILMN has no problem at all paying its short term obligations.
  • ILMN has a Current ratio (2.08) which is comparable to the rest of the industry.
  • ILMN has a Quick Ratio of 1.72. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.72, ILMN is in line with its industry, outperforming 43.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 1.72
ILMN Yearly Current Assets VS Current LiabilitesILMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

5

3. ILMN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 97.96% over the past year.
  • The Earnings Per Share has been growing slightly by 1.51% on average over the past years.
  • The Revenue has decreased by -0.66% in the past year.
  • ILMN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.04% yearly.
EPS 1Y (TTM)97.96%
EPS 3Y31.77%
EPS 5Y1.51%
EPS Q2Q%56.98%
Revenue 1Y (TTM)-0.66%
Revenue growth 3Y-1.78%
Revenue growth 5Y6.04%
Sales Q2Q%4.98%

3.2 Future

  • ILMN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.14% yearly.
  • Based on estimates for the next years, ILMN will show a small growth in Revenue. The Revenue will grow by 6.06% on average per year.
EPS Next Y6.75%
EPS Next 2Y10.5%
EPS Next 3Y9.64%
EPS Next 5Y12.14%
Revenue Next Year5.78%
Revenue Next 2Y5.64%
Revenue Next 3Y5.85%
Revenue Next 5Y6.06%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ILMN Yearly Revenue VS EstimatesILMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
ILMN Yearly EPS VS EstimatesILMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

4

4. ILMN Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 26.71, ILMN can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, ILMN is valued a bit cheaper than 70.18% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of ILMN to the average of the S&P500 Index (26.83), we can say ILMN is valued inline with the index average.
  • The Price/Forward Earnings ratio is 25.03, which means the current valuation is very expensive for ILMN.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ILMN indicates a somewhat cheap valuation: ILMN is cheaper than 71.93% of the companies listed in the same industry.
  • ILMN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.95.
Industry RankSector Rank
PE 26.71
Fwd PE 25.03
ILMN Price Earnings VS Forward Price EarningsILMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 77.19% of the companies in the same industry are more expensive than ILMN, based on the Enterprise Value to EBITDA ratio.
  • 84.21% of the companies in the same industry are more expensive than ILMN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 21.26
EV/EBITDA 17.32
ILMN Per share dataILMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ILMN does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of ILMN may justify a higher PE ratio.
PEG (NY)3.96
PEG (5Y)17.7
EPS Next 2Y10.5%
EPS Next 3Y9.64%

0

5. ILMN Dividend Analysis

5.1 Amount

  • No dividends for ILMN!.
Industry RankSector Rank
Dividend Yield 0%

ILMN Fundamentals: All Metrics, Ratios and Statistics

ILLUMINA INC

NASDAQ:ILMN (3/3/2026, 8:19:32 PM)

Premarket: 129.04 -0.52 (-0.4%)

129.56

-3.33 (-2.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners104.7%
Inst Owner Change-0.86%
Ins Owners0.17%
Ins Owner Change-0.38%
Market Cap19.80B
Revenue(TTM)4.34B
Net Income(TTM)850.00M
Analysts72.31
Price Target138.42 (6.84%)
Short Float %5.2%
Short Ratio3.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.14%
Min EPS beat(2)7.62%
Max EPS beat(2)12.65%
EPS beat(4)4
Avg EPS beat(4)9.22%
Min EPS beat(4)1.33%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)14.29%
EPS beat(12)10
Avg EPS beat(12)229.93%
EPS beat(16)13
Avg EPS beat(16)175.4%
Revenue beat(2)1
Avg Revenue beat(2)1.24%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)2.75%
Revenue beat(4)1
Avg Revenue beat(4)0.08%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)2.75%
Revenue beat(8)3
Avg Revenue beat(8)-0.09%
Revenue beat(12)5
Avg Revenue beat(12)-0.28%
Revenue beat(16)5
Avg Revenue beat(16)-0.88%
PT rev (1m)4.67%
PT rev (3m)14.9%
EPS NQ rev (1m)-6.53%
EPS NQ rev (3m)-4.42%
EPS NY rev (1m)0.04%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)1.3%
Revenue NQ rev (3m)1.96%
Revenue NY rev (1m)3.03%
Revenue NY rev (3m)3.79%
Valuation
Industry RankSector Rank
PE 26.71
Fwd PE 25.03
P/S 4.56
P/FCF 21.26
P/OCF 18.35
P/B 7.27
P/tB 14.14
EV/EBITDA 17.32
EPS(TTM)4.85
EY3.74%
EPS(NY)5.18
Fwd EY4%
FCF(TTM)6.09
FCFY4.7%
OCF(TTM)7.06
OCFY5.45%
SpS28.42
BVpS17.82
TBVpS9.16
PEG (NY)3.96
PEG (5Y)17.7
Graham Number44.1
Profitability
Industry RankSector Rank
ROA 12.79%
ROE 31.22%
ROCE 17.41%
ROIC 13.63%
ROICexc 20.13%
ROICexgc 32.79%
OM 20.29%
PM (TTM) 19.57%
GM 66.61%
FCFM 21.44%
ROA(3y)-6.03%
ROA(5y)-9.81%
ROE(3y)-13.51%
ROE(5y)-20.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y1.94%
ROICexgc growth 5Y5.2%
ROICexc growth 3Y74.03%
ROICexc growth 5Y4.4%
OM growth 3Y36.82%
OM growth 5Y2.01%
PM growth 3YN/A
PM growth 5Y-0.68%
GM growth 3Y0.64%
GM growth 5Y-0.57%
F-Score8
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.14
Debt/EBITDA 1.29
Cap/Depr 54.81%
Cap/Sales 3.41%
Interest Coverage 9.27
Cash Conversion 93.74%
Profit Quality 109.53%
Current Ratio 2.08
Quick Ratio 1.72
Altman-Z 4.35
F-Score8
WACC10.42%
ROIC/WACC1.31
Cap/Depr(3y)45.45%
Cap/Depr(5y)67.5%
Cap/Sales(3y)3.56%
Cap/Sales(5y)5.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.96%
EPS 3Y31.77%
EPS 5Y1.51%
EPS Q2Q%56.98%
EPS Next Y6.75%
EPS Next 2Y10.5%
EPS Next 3Y9.64%
EPS Next 5Y12.14%
Revenue 1Y (TTM)-0.66%
Revenue growth 3Y-1.78%
Revenue growth 5Y6.04%
Sales Q2Q%4.98%
Revenue Next Year5.78%
Revenue Next 2Y5.64%
Revenue Next 3Y5.85%
Revenue Next 5Y6.06%
EBIT growth 1Y36.38%
EBIT growth 3Y34.38%
EBIT growth 5Y8.17%
EBIT Next Year32.05%
EBIT Next 3Y17.05%
EBIT Next 5Y16.57%
FCF growth 1Y31.31%
FCF growth 3YN/A
FCF growth 5Y0.88%
OCF growth 1Y28.91%
OCF growth 3Y40.15%
OCF growth 5Y-0.02%

ILLUMINA INC / ILMN FAQ

Can you provide the ChartMill fundamental rating for ILLUMINA INC?

ChartMill assigns a fundamental rating of 6 / 10 to ILMN.


Can you provide the valuation status for ILLUMINA INC?

ChartMill assigns a valuation rating of 4 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.


How profitable is ILLUMINA INC (ILMN) stock?

ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.


What is the financial health of ILLUMINA INC (ILMN) stock?

The financial health rating of ILLUMINA INC (ILMN) is 7 / 10.


What is the expected EPS growth for ILLUMINA INC (ILMN) stock?

The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 6.75% in the next year.